Cellectar cellectar.com


Public list: Pharma Startups (4732) Portfolio Company Matchmaking M&A (394) Cancer Therapeutics (1137)

Cellectar is a radiopharmaceuticals company that designs, develops, and manufactures products to detect, treat and monitor a wide variety of human cancers. Their product candidates combine lipid-like molecules, phospholipid ethers (PLEs), with radioisotopes that destroy malignant cells.

Cellectar is a radiopharmaceuticals company that designs, develops, and manufactures products to detect, treat and monitor a wide variety of human cancers. Their product candidates combine lipid-like molecules, phospholipid ethers (PLEs), with radioi...Show all

Company (Acquired)

Phone: 608-441-8120

Fax:

3301 Agriculture Drive
8th Floor
Madison, 53716
Wisconsin, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Cellectar $15.7M Apr 12, 2011
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Cellectar Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

OncoMed Pharmaceuticals

Redwood City, California, United States
IPO / Went publicOncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing therapeutics targeting cancer stem cells, or CSCs, which are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. OncoMed has five anti-CSC product candidates in clinical development, including demcizumab (OMP-21M18, anti-DLL4), OMP-59R5 (anti-Notch2/3), OMP-52M51 (anti-Notch1), vantictumab (OMP-18R5, anti-Fzd7), and OMP-54F28 (Fzd8-Fc), which target key cancer s...Show allLogin to see details

Stemina Biomarker Discovery

Madison, Wisconsin, United States
Alive / ActiveStemina Cell Discovery discovers and validates small molecules as biomarkers for high-throughput drug screening and disease diagnostics using an all human system comprised of stem cells and the company's metabolomics platform. Metabolomics aims to enable the discovery of small molecules that can be used as candidate biomarkers of disease and pharmacological efficacy or toxicity. The human embryonic stem cell metabolome is a source of candidate biomarkers to predict, diagnose or measure the progr...Show allLogin to see details
See all 16 competitors